IL129968A0 - use of cntf receptor activators for the treatment of obesity - Google Patents

use of cntf receptor activators for the treatment of obesity

Info

Publication number
IL129968A0
IL129968A0 IL12996897A IL12996897A IL129968A0 IL 129968 A0 IL129968 A0 IL 129968A0 IL 12996897 A IL12996897 A IL 12996897A IL 12996897 A IL12996897 A IL 12996897A IL 129968 A0 IL129968 A0 IL 129968A0
Authority
IL
Israel
Prior art keywords
obesity
treatment
receptor activators
cntf receptor
cntf
Prior art date
Application number
IL12996897A
Other languages
English (en)
Original Assignee
Angeletti P Ist Richerche Bio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angeletti P Ist Richerche Bio filed Critical Angeletti P Ist Richerche Bio
Publication of IL129968A0 publication Critical patent/IL129968A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
IL12996897A 1996-11-19 1997-11-18 use of cntf receptor activators for the treatment of obesity IL129968A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT96RM000790A IT1288388B1 (it) 1996-11-19 1996-11-19 Uso di sostanze che attivano il recettore del cntf ( fattore neurotrofico ciliare) per la preparazione di farmaci per la terapia
PCT/IT1997/000283 WO1998022128A1 (en) 1996-11-19 1997-11-18 Use of cntf (ciliary neurotrophic factor) receptor activators for the treatment of obesity

Publications (1)

Publication Number Publication Date
IL129968A0 true IL129968A0 (en) 2000-02-29

Family

ID=11404538

Family Applications (2)

Application Number Title Priority Date Filing Date
IL12996897A IL129968A0 (en) 1996-11-19 1997-11-18 use of cntf receptor activators for the treatment of obesity
IL12996805A IL129968A (en) 1996-11-19 2005-07-26 Use of cntf receptor activators for the manufacture of a medicament for a medicament for the treatment of obesity

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL12996805A IL129968A (en) 1996-11-19 2005-07-26 Use of cntf receptor activators for the manufacture of a medicament for a medicament for the treatment of obesity

Country Status (14)

Country Link
US (2) US6565869B1 (de)
EP (1) EP0946189B1 (de)
JP (1) JP4067127B2 (de)
CN (2) CN102145163B (de)
AT (1) ATE228003T1 (de)
AU (1) AU727174B2 (de)
CA (1) CA2271781C (de)
DE (1) DE69717308T2 (de)
DK (1) DK0946189T3 (de)
ES (1) ES2187830T3 (de)
IL (2) IL129968A0 (de)
IT (1) IT1288388B1 (de)
PT (1) PT946189E (de)
WO (1) WO1998022128A1 (de)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6472178B1 (en) 1998-02-27 2002-10-29 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding a modified ciliary neurotrophic factor and method of making thereof
IT1288388B1 (it) 1996-11-19 1998-09-22 Angeletti P Ist Richerche Bio Uso di sostanze che attivano il recettore del cntf ( fattore neurotrofico ciliare) per la preparazione di farmaci per la terapia
AU718500B2 (en) 1997-01-23 2000-04-13 Sumitomo Pharmaceuticals Company, Limited Remedies for diabetes
IT1291114B1 (it) 1997-03-20 1998-12-29 Angeletti P Ist Richerche Bio Varianti del fattore neurotrofico ciliare (cntf) con migliorata selettivita' al recettore, e metodo per la loro selezione
US6680291B1 (en) 1998-02-27 2004-01-20 Regeneron Pharmaceuticals, Inc. Modified ciliary neurotrophic factor, method of making and methods of use thereof
CA2368431C (en) 1999-03-29 2006-01-24 The Procter & Gamble Company Melanocortin receptor ligands
AU4651900A (en) * 1999-04-20 2000-11-02 Beth Israel Deaconess Medical Center Methods and compositions for modulating ciliary neurotrophic factor activity
IL132312A0 (en) * 1999-09-05 2001-03-19 Yeda Res & Dev Use of leptin in inhibition of endothelial cell proliferation
AU2001230587A1 (en) * 2000-02-18 2001-08-27 Sumitomo Pharmaceuticals Company, Limited Drugs for ameliorating impaired glucose tolerance
US20030036512A1 (en) * 2000-03-06 2003-02-20 Tsutomu Nakagawa Leptin-resistance amerliorating agents
EP1365785A2 (de) * 2000-05-24 2003-12-03 Regeneron Pharmaceuticals, Inc. Verwendung von ciliary neurotrophic factor
AU2001267058A1 (en) * 2000-06-09 2001-12-17 University Of Florida Research Foundation, Inc. Aav vector-based compositions and therapeutic uses thereof
JP2004529629A (ja) * 2001-03-02 2004-09-30 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 低減された免疫原性を有する修飾された繊毛様神経栄養因子（ｃｎｔｆ）
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20050064555A1 (en) * 2003-07-09 2005-03-24 Xencor, Inc. Ciliary neurotrophic factor variants
ATE547404T1 (de) 2003-09-22 2012-03-15 Msd Kk Piperidinderivate
EP1734963A4 (de) 2004-04-02 2008-06-18 Merck & Co Inc Verfahren zur behandlung von menschen mit metabolischen und anthropometrischen störungen
US7279282B2 (en) * 2004-07-09 2007-10-09 Scott Mellis Methods for identifying a candidate for treatment of obesity
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
CN101094689B (zh) † 2004-11-01 2013-06-12 安米林药品有限责任公司 治疗肥胖以及肥胖相关疾病和病症的方法
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
BRPI0610580B8 (pt) 2005-05-30 2021-05-25 Banyu Pharma Co Ltd composto derivado de piperidina
JPWO2007018248A1 (ja) 2005-08-10 2009-02-19 萬有製薬株式会社 ピリドン化合物
WO2007024004A1 (ja) 2005-08-24 2007-03-01 Banyu Pharmaceutical Co., Ltd. フェニルピリドン誘導体
WO2007029847A1 (ja) 2005-09-07 2007-03-15 Banyu Pharmaceutical Co., Ltd. 二環性芳香族置換ピリドン誘導体
EP1940842B1 (de) 2005-09-29 2012-05-30 Merck Sharp & Dohme Corp. Acylierte spiropiperidinderivate als modulatoren des melanocortin-4-rezeptors
JP2009512715A (ja) 2005-10-21 2009-03-26 ノバルティス アクチエンゲゼルシャフト レニン阻害剤と抗異脂肪血症剤および／または抗肥満症剤の組み合わせ
EP1944301A4 (de) 2005-10-27 2012-01-04 Msd Kk Neue benzoxathiinderivate
ES2381205T3 (es) 2005-11-10 2012-05-24 Msd K.K. Derivado espiro aza-sustituido
US8173629B2 (en) 2006-09-22 2012-05-08 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20090247560A1 (en) 2006-09-28 2009-10-01 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
JP5319518B2 (ja) 2007-04-02 2013-10-16 Ｍｓｄ株式会社 インドールジオン誘導体
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
EP2264026A4 (de) 2008-03-06 2012-03-28 Msd Kk Alkylaminopyridinderivate
WO2009119726A1 (ja) 2008-03-28 2009-10-01 萬有製薬株式会社 メラニン凝集ホルモン受容体拮抗作用を有するジアリールメチルアミド誘導体
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
JPWO2009154132A1 (ja) 2008-06-19 2011-12-01 Ｍｓｄ株式会社 スピロジアミン−ジアリールケトオキシム誘導体
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
EP2319841A1 (de) 2008-07-30 2011-05-11 Msd K.K. (5-gliedriges)-(5-gliedriges) oder (5-gliedriges)-(6-gliedriges) kondensiertes ringcycloalkylaminderivat
EP2348857B1 (de) 2008-10-22 2016-02-24 Merck Sharp & Dohme Corp. Neue cyclische benzimidazolderivate als antidiabetika
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
EP2379547A1 (de) 2008-12-16 2011-10-26 Schering Corporation Pyridopyrimidinderivate und verfahren zu deren anwendung
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
SG192941A1 (en) 2011-02-25 2013-09-30 Merck Sharp & Dohme Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
RU2015106909A (ru) 2012-08-02 2016-09-27 Мерк Шарп И Доум Корп. Антидиабетические трициклические соединения
KR20150118158A (ko) 2013-02-22 2015-10-21 머크 샤프 앤드 돔 코포레이션 항당뇨병 비시클릭 화합물
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
AU2014235215A1 (en) 2013-03-15 2015-10-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
BR112015030326A2 (pt) 2013-06-05 2017-08-29 Synergy Pharmaceuticals Inc Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CN104558148B (zh) * 2013-10-17 2018-11-06 北京生物制品研究所有限责任公司 睫状神经营养因子突变体及其修饰型突变体和用途
KR102431436B1 (ko) 2014-08-29 2022-08-10 테스 파마 에스.알.엘. α-아미노-β-카복시뮤콘산 세미알데히드 데카복실라제의 억제제
CN107073077B (zh) * 2014-11-07 2020-12-01 陕西麦科奥特科技有限公司 睫状神经营养因子鼻腔给药系统及其制备方法和应用
CN106632650B (zh) * 2015-10-30 2020-11-13 北京生物制品研究所有限责任公司 睫状神经营养因子突变体及其修饰型突变体和应用
WO2018069532A1 (en) 2016-10-14 2018-04-19 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
EP3558298B1 (de) 2016-12-20 2026-03-11 Merck Sharp & Dohme LLC Antidiabetische spirochromanverbindungen
WO2018128745A1 (en) * 2017-01-06 2018-07-12 The Board Of Trustees Of The Leland Stanford Junior University Ciliary neurotrophic factor receptor ligands and methods of using the same
SG11202005146VA (en) * 2017-12-18 2020-06-29 Regeneron Pharma Bispecific antigen binding molecules that bind leptin receptor and/or gp130, and methods of use thereof
PT3773713T (pt) 2018-04-06 2025-07-29 Regeneron Pharma Anticorpo agonista do recetor de leptina para usar no aumento da massa óssea num sujeito que sofre de disfunção metabólica ou de hipoleptinemia
WO2019246141A1 (en) * 2018-06-19 2019-12-26 Cella Therapeutics, Llc DRUG DELIVERY SYSTEMS COMPRISING A NEUROTROPHIC AGENT, AN APOPTOSIS SIGNALING FRAGMENT INHIBITOR (FAS) OR FAS LIGAND (FASL) INHIBITOR, A TUMOR NECROSIS FACTOR-α (TNF-α) OR TNF RECEPTOR INHIBITOR, A MITOCHONDRIAL PEPTIDE, AN OLIGONUCLEOTIDE, A CHEMOKINE INHIBITOR, OR A CYSTEINE-ASPARTIC PROTEASE
CN112566622A (zh) * 2018-06-19 2021-03-26 细胞疗法有限责任公司 用于治疗青光眼或高眼压症的包含眼内压降低剂、cnp化合物、npr-b化合物、tie-2激动剂或神经营养剂的缓释药物递送系统
WO2020023621A1 (en) * 2018-07-24 2020-01-30 Puneeth Iyengar Improved weight loss therapy
AR117122A1 (es) 2018-11-20 2021-07-14 Tes Pharma S R L INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA
US20230094423A1 (en) * 2019-12-18 2023-03-30 Cella Therapeutics, Llc Drug delivery systems comprising a neurotrophic agent, an apoptosis signaling fragment inhibitor (fas) or fas ligand (fasl) inhibitor, a tumor necrosis factor-alpha (tnf-alpha) or tnf receptor inhibitor, a mitochondrial peptide, an oligonucleotide, a chemokine inhibitor, or a cysteine-aspartic protease inhibitor

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166317A (en) 1988-10-31 1992-11-24 Houston Biotechnology Incorporated Neurotrophic factor
US5011914A (en) 1989-01-05 1991-04-30 Collins Franklin D Purified ciliary neurotrophic factor
US5141856A (en) 1989-01-05 1992-08-25 Synergen, Inc. Expression of purified ciliary neurotrophic factor
US4997929A (en) 1989-01-05 1991-03-05 Synergen, Inc. Purified ciliary neurotrophic factor
IE903130A1 (en) 1989-09-15 1991-03-27 Regeneron Pharma Ciliary neurotrophic factor
US5426177A (en) 1990-06-01 1995-06-20 Regeneron Pharmaceuticals, Inc. Ciliary neurotrophic factor receptor
CS156891A3 (en) 1990-06-01 1992-04-15 Regeneron Pharma Receptor of a cilary neurotropic factor
CN1061623A (zh) 1990-06-01 1992-06-03 里珍纳龙药品有限公司 睫状神经营养性因子受体
US5691313A (en) 1991-07-23 1997-11-25 Amgen Inc. Methods of treating impotency with ciliary neurotrophic factor
WO1993002206A1 (en) 1991-07-23 1993-02-04 Syntex-Synergen Neuroscience Joint Venture Purification of recombinant ciliary neurotrophic factor and c-terminal truncated ciliary neurotrophic factor and methods for treating peripheral nerve damage
US5593857A (en) 1991-08-23 1997-01-14 Scios Inc. Production of homogeneous truncated CNTF
EP0668911A1 (de) 1991-11-11 1995-08-30 FIDIA S.p.A. Synthese und reinigung von unvollständigen und mutierten formen des humanen ciliaren neurotrophen faktors
US5955290A (en) 1991-12-02 1999-09-21 Regeneron Pharmaceuticals, Inc. Assay systems using the CNTF signal transduction pathway
US5349056A (en) 1992-10-09 1994-09-20 Regeneron Pharmaceuticals Modified ciliary neurotrophic factors
US5470952A (en) 1993-10-20 1995-11-28 Regeneron Pharmaceuticals, Inc. CNTF and IL-6 antagonists
US6143714A (en) 1994-10-24 2000-11-07 Regeneron Pharmaceuticals, Inc. Methods of using hepatocyte growth factor to promote survival, growth and differentiation of motor neurons
IT1284867B1 (it) * 1996-07-10 1998-05-22 Angeletti P Ist Richerche Bio Varianti del fattore neurotrofico ciliare umano (hcntf) con uno spettro di azione differente dalla molecola di tipo selvatico
IT1288388B1 (it) 1996-11-19 1998-09-22 Angeletti P Ist Richerche Bio Uso di sostanze che attivano il recettore del cntf ( fattore neurotrofico ciliare) per la preparazione di farmaci per la terapia

Also Published As

Publication number Publication date
PT946189E (pt) 2003-02-28
ATE228003T1 (de) 2002-12-15
ITRM960790A0 (it) 1996-11-19
IL129968A (en) 2005-11-20
US6960558B2 (en) 2005-11-01
EP0946189A1 (de) 1999-10-06
US20030176346A1 (en) 2003-09-18
CN102145163A (zh) 2011-08-10
JP2000511561A (ja) 2000-09-05
WO1998022128A1 (en) 1998-05-28
CN102145163B (zh) 2013-09-18
ES2187830T3 (es) 2003-06-16
IT1288388B1 (it) 1998-09-22
EP0946189B1 (de) 2002-11-20
CN101703761B (zh) 2013-11-20
US6565869B1 (en) 2003-05-20
AU727174B2 (en) 2000-12-07
ITRM960790A1 (it) 1998-05-19
DK0946189T3 (da) 2002-12-16
CA2271781A1 (en) 1998-05-28
DE69717308D1 (de) 2003-01-02
DE69717308T2 (de) 2003-07-10
CN101703761A (zh) 2010-05-12
AU5134498A (en) 1998-06-10
CA2271781C (en) 2002-11-12
JP4067127B2 (ja) 2008-03-26

Similar Documents

Publication Publication Date Title
IL129968A0 (en) use of cntf receptor activators for the treatment of obesity
IL128003A0 (en) Therapeutic multispecific compounds comprised of anti-fcalpha receptor antibodies
AU3508497A (en) Androgen receptor modulator compounds and methods
MX9700553A (es) Anticuerpos que activan un receptor de eritropoyetina.
MX9805255A (es) Antagonistas de receptor de vitronectina.
MX9603928A (es) Receptores trk humanos e inhibidores del factor neurotrofico.
EP1382597A3 (de) Steroidrezeptor-Modulator Verbindungen und Methoden
CY2610B2 (en) Prevention and treatment of skeletal disorder with EP2 receptor subtype selective prostaglandin E2 a gonists
BG103548A (en) Vitronectine receptor antagonists
DE69524623D1 (de) Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen
PL329212A1 (en) Tetrahydro-beta-carbolynic compounds
AU6485496A (en) Compounds and methods for treatment of egf receptor associated cancers and purification of the egf receptor
IL97927A0 (en) Soluble,truncated gamma-interferon receptors
IL117159A0 (en) Immunotherapeutic methods and compositions for screening prognosis and therapy
UA72875C2 (uk) БІЛКИ, ЯКІ ЗВ'ЯЗУЮТЬСЯ З <font face="Symbol">b</font>-АМІЛОЇДНИМ ПЕПТИДОМ ТА ПОЛІНУКЛЕОТИДИ, ЩО ЇХ КОДУЮТЬ
GB0010488D0 (en) Glutamate receptor modulators and the treatment of psychiatric disorders
ZA983391B (en) Process of producing iron carbide from granular sponge iron.
ZA968790B (en) Combination antiemetic therapy using NK-1 receptor antagonists.
MX9706967A (es) Indazolcarboxamidas.
IL119528A0 (en) NK-1 receptor antagonists for the treatment of cancer
ZA984161B (en) Apparatus for generating stimulating signals
IT1276508B1 (it) Plantare ortopedico a stimolazione variabile.
SI0914321T1 (en) Indole derivatives for the treatment of osteoporosis
HU9501757D0 (en) Bridle of bearing, especially for treating spine ailment
GB9517240D0 (en) Vibratory screening apparatus